The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Tissue Therapy

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Tissue Therapy


High impact information on Tissue Therapy

  • Stem cell controversy to stall European tissue and cell therapy rules [6].
  • The identification of p63 as a keratinocyte stem cell marker will be of practical importance for the clinical application of epithelial cultures in cell therapy as well as for studies on epithelial tumorigenesis [7].
  • Cell therapy of VLCAD deficiency was related to drug-induced increases in VLCAD mRNA (+44 to +150%; P<0.001), protein (1.5-2-fold) and residual enzyme activity (up to 7.7-fold) in patient cells [8].
  • Relapse was reversed by allogeneic cell therapy in 2/3 cases, currently with no residual host DNA (male) by cytogenetic analysis and polymerase chain reaction [9].
  • In Crigler-Najjar type II patients and, recently, in Crigler-Najjar type I patients treated with human hepatocyte cell therapy, phenobarbital has been used for reducing the serum bilirubin load [10].

Chemical compound and disease context of Tissue Therapy


Biological context of Tissue Therapy


Anatomical context of Tissue Therapy


Associations of Tissue Therapy with chemical compounds

  • Patients with PFIC3 due to MDR3 deficiency may benefit from ursodeoxycholic acid therapy and could be good candidates for cell therapy in the future [20].
  • CONCLUSIONS: Doxorubicin-induced hepatic endothelial damage enhanced cell engraftment, which should be useful in cell therapy strategies [21].
  • Despite this, when tested in gene-directed enzyme prodrug therapy cell cytotoxicity studies, cells expressing wtNR or mtNR had similar sensitivity to the prodrug CB1954 and mounted similar bystander killing effects [22].
  • Only early intervention with gamma-aminobutyric acid cell therapy is able to reverse neuropathic pain after partial nerve injury [23].
  • Cell therapy using microencapsulated 293 cells transfected with a gene construct expressing CYP2B1, an ifosfamide converting enzyme, instilled intra-arterially in patients with advanced-stage pancreatic carcinoma: a phase I/II study [24].

Gene context of Tissue Therapy

  • OBJECTIVE: We aimed to achieve angiogenic synergism between human vascular endothelial growth factor 165 (VEGF 165 ) and angiopoietin-1 (Ang-1) using a new adenoviral bicistronic vector concurrently with cell therapy to repair an ischemically damaged hind limb in a rabbit model [25].
  • The controlled regulation of HGF/c-met expression may be beneficial in tissue engineering and cell therapy employing hMSC [26].
  • This work describes the first successful oligodendrocyte-based cell therapy for presymptomatic arylsulfatase A (ARSA) null neonate mice, a murine model for human metachromatic leukodystrophy (MLD) [27].
  • Gene and cell therapy strategies aim to restore the dystrophin-associated protein complex [28].
  • Moreover, apparently with the exception of one or two reagents (16H5 and possibly B-F5) routine laboratory parameters which are helpful in determining disease activity such as CRP or the rheumatoid factor usually remain unaltered with anti-T cell therapy [29].

Analytical, diagnostic and therapeutic context of Tissue Therapy

  • Western blot analysis revealed that cell therapy modulated expression of molecules in the VEGF, MCP-1, and angiopoietin pathways [30].
  • On leukopheresis products obtained from patients included in a protocol interleukin-2/lymphokine-activated killer (IL-2/LAK) cell therapy, we analyzed, in parallel with the standard culture and on large volumes of these products, different parameters which could either improve LAK cell enhancement or simplify the procedure [31].


  1. Adoptive cellular immunotherapy of human ovarian carcinoma xenografts in nude mice. Ortaldo, J.R., Porter, H.R., Miller, P., Stevenson, H.C., Ozols, R.F., Hamilton, T.C. Cancer Res. (1986) [Pubmed]
  2. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. Comoli, P., Pedrazzoli, P., Maccario, R., Basso, S., Carminati, O., Labirio, M., Schiavo, R., Secondino, S., Frasson, C., Perotti, C., Moroni, M., Locatelli, F., Siena, S. J. Clin. Oncol. (2005) [Pubmed]
  3. Implants of polymer-encapsulated human NGF-secreting cells in the nonhuman primate: rescue and sprouting of degenerating cholinergic basal forebrain neurons. Emerich, D.F., Winn, S.R., Harper, J., Hammang, J.P., Baetge, E.E., Kordower, J.H. J. Comp. Neurol. (1994) [Pubmed]
  4. Paracrine secretion of transforming growth factor-beta1 in aneurysm healing and stabilization with endovascular smooth muscle cell therapy. Losy, F., Dai, J., Pages, C., Ginat, M., Muscatelli-Groux, B., Guinault, A.M., Rousselle, E., Smedile, G., Loisance, D., Becquemin, J.P., Allaire, E. J. Vasc. Surg. (2003) [Pubmed]
  5. Induction of HL-60 cells to undergo apoptosis is determined by high levels of wild-type p53 protein whereas differentiation of the cells is mediated by lower p53 levels. Ronen, D., Schwartz, D., Teitz, Y., Goldfinger, N., Rotter, V. Cell Growth Differ. (1996) [Pubmed]
  6. Stem cell controversy to stall European tissue and cell therapy rules. Sheridan, C. Nat. Biotechnol. (2006) [Pubmed]
  7. p63 identifies keratinocyte stem cells. Pellegrini, G., Dellambra, E., Golisano, O., Martinelli, E., Fantozzi, I., Bondanza, S., Ponzin, D., McKeon, F., De Luca, M. Proc. Natl. Acad. Sci. U.S.A. (2001) [Pubmed]
  8. Bezafibrate increases very-long-chain acyl-CoA dehydrogenase protein and mRNA expression in deficient fibroblasts and is a potential therapy for fatty acid oxidation disorders. Djouadi, F., Aubey, F., Schlemmer, D., Ruiter, J.P., Wanders, R.J., Strauss, A.W., Bastin, J. Hum. Mol. Genet. (2005) [Pubmed]
  9. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Slavin, S., Nagler, A., Naparstek, E., Kapelushnik, Y., Aker, M., Cividalli, G., Varadi, G., Kirschbaum, M., Ackerstein, A., Samuel, S., Amar, A., Brautbar, C., Ben-Tal, O., Eldor, A., Or, R. Blood (1998) [Pubmed]
  10. Expression and inducibility of the human bilirubin UDP-glucuronosyltransferase UGT1A1 in liver and cultured primary hepatocytes: evidence for both genetic and environmental influences. Ritter, J.K., Kessler, F.K., Thompson, M.T., Grove, A.D., Auyeung, D.J., Fisher, R.A. Hepatology (1999) [Pubmed]
  11. Artificial cells for bioencapsulation of cells and genetically engineered E. coli. For cell therapy, gene therapy, and removal of urea and ammonia. Chang, T.M., Prakash, S. Methods Mol. Biol. (1997) [Pubmed]
  12. Application of autologous hematopoietic cell therapy to a nonhuman primate model of heterogeneous high-dose irradiation. Bertho, J.M., Prat, M., Frick, J., Demarquay, C., Gaugler, M.H., Dudoignon, N., Clairand, I., Chapel, A., Gorin, N.C., Thierry, D., Gourmelon, P. Radiat. Res. (2005) [Pubmed]
  13. Genetically engineered pancreatic beta-cell lines for cell therapy of diabetes. Efrat, S. Ann. N. Y. Acad. Sci. (1999) [Pubmed]
  14. Human marrow-derived mesenchymal stem cells (MSCs) express hematopoietic cytokines and support long-term hematopoiesis when differentiated toward stromal and osteogenic lineages. Majumdar, M.K., Thiede, M.A., Haynesworth, S.E., Bruder, S.P., Gerson, S.L. J. Hematother. Stem Cell Res. (2000) [Pubmed]
  15. Further characterization of embryonic stem cell-derived radial glial cells. Liour, S.S., Kraemer, S.A., Dinkins, M.B., Su, C.Y., Yanagisawa, M., Yu, R.K. Glia (2006) [Pubmed]
  16. The effects of transplantation of osteoblastic cells with bone morphogenetic protein (BMP)/carrier complex on bone repair. Tamura, S., Kataoka, H., Matsui, Y., Shionoya, Y., Ohno, K., Michi, K.I., Takahashi, K., Yamaguchi, A. Bone (2001) [Pubmed]
  17. Effects of development of host immunity on the biodistribution of xenogeneic MHC non-restricted cytotoxic T cells: implications for adoptive cell therapy of cancer. Cesano, A., Wortman, J.A., Pourdehnad, M., Visonneau, S., Mozley, D., Bhatnagar, A., Alavi, A., Santoli, D. Int. J. Oncol. (1999) [Pubmed]
  18. Skeletal myogenic differentiation of mesenchymal stem cells isolated from human umbilical cord blood. Gang, E.J., Jeong, J.A., Hong, S.H., Hwang, S.H., Kim, S.W., Yang, I.H., Ahn, C., Han, H., Kim, H. Stem Cells (2004) [Pubmed]
  19. Sustained secretion of ciliary neurotrophic factor to the vitreous, using the encapsulated cell therapy-based NT-501 intraocular device. Thanos, C.G., Bell, W.J., O'Rourke, P., Kauper, K., Sherman, S., Stabila, P., Tao, W. Tissue engineering. (2004) [Pubmed]
  20. Role of multidrug resistance 3 deficiency in pediatric and adult liver disease: one gene for three diseases. Jacquemin, E. Semin. Liver Dis. (2001) [Pubmed]
  21. Regulation of hepatocyte engraftment and proliferation after cytotoxic drug-induced perturbation of the rat liver. Kim, K.S., Joseph, B., Inada, M., Gupta, S. Transplantation (2005) [Pubmed]
  22. Appropriate subcellular localisation of prodrug-activating enzymes has important consequences for suicide gene therapy. Spooner, R.A., Maycroft, K.A., Paterson, H., Friedlos, F., Springer, C.J., Marais, R. Int. J. Cancer (2001) [Pubmed]
  23. Only early intervention with gamma-aminobutyric acid cell therapy is able to reverse neuropathic pain after partial nerve injury. Stubley, L.A., Martinez, M.A., Karmally, S., Lopez, T., Cejas, P., Eaton, M.J. J. Neurotrauma (2001) [Pubmed]
  24. Cell therapy using microencapsulated 293 cells transfected with a gene construct expressing CYP2B1, an ifosfamide converting enzyme, instilled intra-arterially in patients with advanced-stage pancreatic carcinoma: a phase I/II study. Löhr, M., Bago, Z.T., Bergmeister, H., Ceijna, M., Freund, M., Gelbmann, W., Günzburg, W.H., Jesnowski, R., Hain, J., Hauenstein, K., Henninger, W., Hoffmeyer, A., Karle, P., Kröger, J.C., Kundt, G., Liebe, S., Losert, U., Müller, P., Probst, A., Püschel, K., Renner, M., Renz, R., Saller, R., Salmons, B., Walter, I. J. Mol. Med. (1999) [Pubmed]
  25. Autologous skeletal myoblasts transduced with a new adenoviral bicistronic vector for treatment of hind limb ischemia. Niagara, M.I., Haider, H.K.h., Ye, L., Koh, V.S., Lim, Y.T., Poh, K.K., Ge, R., Sim, E.K. J. Vasc. Surg. (2004) [Pubmed]
  26. Functional expression of HGF and HGF receptor/c-met in adult human mesenchymal stem cells suggests a role in cell mobilization, tissue repair, and wound healing. Neuss, S., Becher, E., Wöltje, M., Tietze, L., Jahnen-Dechent, W. Stem Cells (2004) [Pubmed]
  27. Oligodendroglial progenitor cell therapy limits central neurological deficits in mice with metachromatic leukodystrophy. Givogri, M.I., Galbiati, F., Fasano, S., Amadio, S., Perani, L., Superchi, D., Morana, P., Del Carro, U., Marchesini, S., Brambilla, R., Wrabetz, L., Bongarzone, E. J. Neurosci. (2006) [Pubmed]
  28. Restoration of dystrophin expression in cultured hybrid myotubes. Radojevic, V., Oppliger, C., Gaschen, F., Burgunder, J.M. Neuropathol. Appl. Neurobiol. (2002) [Pubmed]
  29. Management of early inflammatory arthritis. Intervention with immunomodulatory agents: monoclonal antibody therapy. Burmester, G.R., Horneff, G., Emmrich, F. Baillière's clinical rheumatology. (1992) [Pubmed]
  30. Differential healing activities of CD34+ and CD14+ endothelial cell progenitors. Awad, O., Dedkov, E.I., Jiao, C., Bloomer, S., Tomanek, R.J., Schatteman, G.C. Arterioscler. Thromb. Vasc. Biol. (2006) [Pubmed]
  31. Lymphokine-activated killer cell expansion for clinical trials of adoptive immunotherapy with interleukin-2: optimization of the culture technique. Favrot, M.C., Coze, C., Combaret, V., Gaspard, M., Colin, C., Franks, C., Negrier, S., Philip, I., Philip, T. Mol. Biother. (1990) [Pubmed]
WikiGenes - Universities